0000950170-24-098235.txt : 20240816
0000950170-24-098235.hdr.sgml : 20240816
20240816202629
ACCESSION NUMBER: 0000950170-24-098235
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240816
FILED AS OF DATE: 20240816
DATE AS OF CHANGE: 20240816
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tingley Whittemore
CENTRAL INDEX KEY: 0001868494
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40656
FILM NUMBER: 241218029
MAIL ADDRESS:
STREET 1: C/O TENAYA THERAPEUTICS, INC.
STREET 2: 171 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tenaya Therapeutics, Inc.
CENTRAL INDEX KEY: 0001858848
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813789973
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD., SUITE 500
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-865-2066
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD., SUITE 500
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2024-08-16
false
0001858848
Tenaya Therapeutics, Inc.
TNYA
0001868494
Tingley Whittemore
C/O TENAYA THERAPEUTICS, INC.
171 OYSTER POINT BLVD., 5TH FLOOR
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Medical Officer
false
Common Stock
2024-08-16
4
S
false
5803
2.8945
D
108731
D
Common Stock
2024-08-16
4
S
false
1625
2.8945
D
107106
D
Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.79 to $3.02. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Includes 63,750 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 6,000 shares of common stock acquired pursuant to the Tenaya Therapeutics, Inc. 2021 Employee Stock Purchase Plan on June 10, 2024.
Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.
/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact
2024-08-16